Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Noopur S. Raje; Elias Anaissie; Shaji K. Kumar; Sagar Lonial; Thomas Martin; Morie A. Gertz; Amrita Krishnan; Parameswaran Hari; Heinz Ludwig; Elizabeth O'Donnell; Andrew Yee; Jonathan L. Kaufman; Adam D. Cohen; Laurent Garderet; Ashutosh F. Wechalekar; Evangelos Terpos; Navin Khatry; Ruben Niesvizky; Qing Yi; Douglas E. Joshua; Tapan Saikia; Nelson Leung; Monika Engelhardt; Mohamad Mothy; Andrew Branagan; Ajai Chari; Anthony J. Reiman; Brea Lipe; Joshua Richter; S. Vincent Rajkumar; Jesús San Miguel; Kenneth C. Anderson; Edward A. Stadtmauer; Rao H. Prabhala; Phillip L. McCarthy; Nikhil C. Munshi

doi:10.1016/S2352-3026(21)00283-0

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Noopur S. Raje, Elias Anaissie, Shaji K. Kumar, Sagar Lonial, Thomas Martin, Morie A. Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O'Donnell, Andrew Yee, Jonathan L. Kaufman, Adam D. Cohen, Laurent Garderet, Ashutosh F. Wechalekar, Evangelos Terpos, Navin Khatry, Ruben Niesvizky, Qing Yi, Douglas E. JoshuaTapan Saikia, Nelson Leung, Monika Engelhardt, Mohamad Mothy, Andrew Branagan, Ajai Chari, Anthony J. Reiman, Brea Lipe, Joshua Richter, S. Vincent Rajkumar, Jesús San Miguel, Kenneth C. Anderson, Edward A. Stadtmauer, Rao H. Prabhala, Phillip L. McCarthy, Nikhil C. Munshi

Hematology

Research output: Contribution to journal › Review article › peer-review

Abstract

Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.

Original language	English (US)
Pages (from-to)	e143-e161
Journal	The Lancet Haematology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1016/S2352-3026(21)00283-0
State	Published - Feb 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1016/S2352-3026(21)00283-0

Cite this

Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., Yee, A., Kaufman, J. L., Cohen, A. D., Garderet, L., Wechalekar, A. F., Terpos, E., Khatry, N., Niesvizky, R., Yi, Q., ... Munshi, N. C. (2022). Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet Haematology, 9(2), e143-e161. https://doi.org/10.1016/S2352-3026(21)00283-0

Raje, NS, Anaissie, E, Kumar, SK, Lonial, S, Martin, T, Gertz, MA, Krishnan, A, Hari, P, Ludwig, H, O'Donnell, E, Yee, A, Kaufman, JL, Cohen, AD, Garderet, L, Wechalekar, AF, Terpos, E, Khatry, N, Niesvizky, R, Yi, Q, Joshua, DE, Saikia, T, Leung, N, Engelhardt, M, Mothy, M, Branagan, A, Chari, A, Reiman, AJ, Lipe, B, Richter, J, Rajkumar, SV, Miguel, JS, Anderson, KC, Stadtmauer, EA, Prabhala, RH, McCarthy, PL & Munshi, NC 2022, 'Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group', The Lancet Haematology, vol. 9, no. 2, pp. e143-e161. https://doi.org/10.1016/S2352-3026(21)00283-0

@article{2843f3df56cd4b01a19b24519c5bbc0e,

title = "Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group",

abstract = "Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.",

author = "Raje, {Noopur S.} and Elias Anaissie and Kumar, {Shaji K.} and Sagar Lonial and Thomas Martin and Gertz, {Morie A.} and Amrita Krishnan and Parameswaran Hari and Heinz Ludwig and Elizabeth O'Donnell and Andrew Yee and Kaufman, {Jonathan L.} and Cohen, {Adam D.} and Laurent Garderet and Wechalekar, {Ashutosh F.} and Evangelos Terpos and Navin Khatry and Ruben Niesvizky and Qing Yi and Joshua, {Douglas E.} and Tapan Saikia and Nelson Leung and Monika Engelhardt and Mohamad Mothy and Andrew Branagan and Ajai Chari and Reiman, {Anthony J.} and Brea Lipe and Joshua Richter and Rajkumar, {S. Vincent} and Miguel, {Jes{\'u}s San} and Anderson, {Kenneth C.} and Stadtmauer, {Edward A.} and Prabhala, {Rao H.} and McCarthy, {Phillip L.} and Munshi, {Nikhil C.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = feb,

doi = "10.1016/S2352-3026(21)00283-0",

language = "English (US)",

volume = "9",

pages = "e143--e161",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "2",

}

TY - JOUR

T1 - Consensus guidelines and recommendations for infection prevention in multiple myeloma

T2 - a report from the International Myeloma Working Group

AU - Raje, Noopur S.

AU - Anaissie, Elias

AU - Kumar, Shaji K.

AU - Lonial, Sagar

AU - Martin, Thomas

AU - Gertz, Morie A.

AU - Krishnan, Amrita

AU - Hari, Parameswaran

AU - Ludwig, Heinz

AU - O'Donnell, Elizabeth

AU - Yee, Andrew

AU - Kaufman, Jonathan L.

AU - Cohen, Adam D.

AU - Garderet, Laurent

AU - Wechalekar, Ashutosh F.

AU - Terpos, Evangelos

AU - Khatry, Navin

AU - Niesvizky, Ruben

AU - Yi, Qing

AU - Joshua, Douglas E.

AU - Saikia, Tapan

AU - Leung, Nelson

AU - Engelhardt, Monika

AU - Mothy, Mohamad

AU - Branagan, Andrew

AU - Chari, Ajai

AU - Reiman, Anthony J.

AU - Lipe, Brea

AU - Richter, Joshua

AU - Rajkumar, S. Vincent

AU - Miguel, Jesús San

AU - Anderson, Kenneth C.

AU - Stadtmauer, Edward A.

AU - Prabhala, Rao H.

AU - McCarthy, Phillip L.

AU - Munshi, Nikhil C.

PY - 2022/2

Y1 - 2022/2

N2 - Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.

AB - Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.

UR - http://www.scopus.com/inward/record.url?scp=85123758879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123758879&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(21)00283-0

DO - 10.1016/S2352-3026(21)00283-0

M3 - Review article

C2 - 35114152

AN - SCOPUS:85123758879

SN - 2352-3026

VL - 9

SP - e143-e161

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 2

ER -

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this